CanSinoBIO’s vaccine is a recombinant viral vector vaccine, a class of vaccines that use a modified version of a different virus to deliver instructions to cells that trigger an immune response.

The vaccine candidate is being evaluated in a ring vaccination trial as part of a comprehensive public health response NEW YORK CITY, NY / ACCESS ...

The causative agent, CSF virus (CSFV), is an enveloped, positive-sense ... detailed experiments to determine the minimum immune dose and immune duration period in piglets. Overall, the recombinant ...

Introduction: Homologous recombination is an effective way to generate recombinant viruses for vaccine research such as pseudorabies virus (PRV ... Enquist (Princeton University) for kindly providing ...

Fortress Biotech and its subsidiary Helocyte have announced the dosing of the first subject in a multi-centre Phase II trial ...

The persistence of latent viral reservoirs remains the major obstacle to eradicating human immunodeficiency ... During the initial week, each mouse was subcutaneously administered a vaccination of ...

Notable examples include the development of Ebola and COVID-19 vaccines using adenoviral and other viral vector platforms. As the field of viral vector technology continues to evolve, several areas of ...

Alas, the same can not be said for the development of vaccines against hepatitis C virus (HCV), discovered more than 30 years ago. Most recently, Kimberly Page and colleagues reported the results of a ...